Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.66 |
| ▸ | MEN1 | O00255 | 8/20 | 0.66 |
| ▸ | AMY1A | P0DUB6 | 5/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443679 | 1.00 | GAA (0.69) | GAAKMT2AMEN1AMY1AL3MBTL1 | |
| SCHEMBL443680 | 1.00 | GAA (0.69) | GAAKMT2AMEN1AMY1AL3MBTL1 | |
| SCHEMBL11049070 | 0.78 | KMT2A (0.71) | GAAKMT2AMEN1AMY1AL3MBTL1 | |
| SCHEMBL28967908 | 0.74 | GAA (0.71) | GAAKMT2AMEN1AMY1AL3MBTL1 | |
| SCHEMBL28476009 | 0.74 | GAA (0.71) | GAAKMT2AMEN1AMY1AL3MBTL1 | |
| SCHEMBL3134925 | 0.72 | KMT2A (0.74) | GAAKMT2AMEN1AMY1AL3MBTL1 | |
| SCHEMBL3134918 | 0.72 | KMT2A (0.74) | GAAKMT2AMEN1AMY1AL3MBTL1 | |
| SCHEMBL10035997 | 0.72 | KMT2A (0.81) | GAAKMT2AMEN1L3MBTL1POLB | |
| SCHEMBL28967916 | 0.72 | KMT2A (0.81) | GAAKMT2AMEN1L3MBTL1POLB | |
| SCHEMBL28476008 | 0.72 | KMT2A (0.81) | GAAKMT2AMEN1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335517-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | RENASCIENCE CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140335517-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | RENASCIENCE CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8809329-B2 | Detection and treatment of schizophrenia | TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809329-B2 | Detection and treatment of schizophrenia | TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2011-02-03 | — | — | US | disclosed |
| US-7645882-B2 | Inhibitor of protein modification products formation | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2010-01-12 | — | — | US | disclosed |
| US-7645882-B2 | Inhibitor of protein modification products formation | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070123577-A1 | Inhibitor of protein modification products formation | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070123577-A1 | Inhibitor of protein modification products formation | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123577-A1 | Inhibitor of protein modification products formation | SERPINB6, PROC, PLPBP | GAA 3516/4885KMT2A 2334/4885MEN1 1277/4885 |
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | GAA 833/4885KMT2A 1703/4885MEN1 4818/4885 |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | GAA 833/4885KMT2A 1703/4885MEN1 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.